INVEGA TRINZA Drug Patent Profile

When do Invega Trinza patents expire, and what generic alternatives are available?

Invega Trinza is a drug marketed by Janssen Pharms and is included in one NDA. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-nine patent family members in twenty-seven countries.

The generic ingredient in INVEGA TRINZA is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Generic Entry Outlook for Invega Trinza

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (paliperidone palmitate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for INVEGA TRINZA

International Patents:	59
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Patent Applications:	305
Drug Prices:	Drug price information for INVEGA TRINZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVEGA TRINZA
What excipients (inactive ingredients) are in INVEGA TRINZA?	INVEGA TRINZA excipients list
DailyMed Link:	INVEGA TRINZA at DailyMed

See drug prices for INVEGA TRINZA

Pharmacology for INVEGA TRINZA

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for INVEGA TRINZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	273 mg/0.875 mL and 410 mg/1.315 mL	207946	1	2021-07-14
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	819 mg/2.625 mL	207946	1	2021-04-30
INVEGA TRINZA	Extended-release Injectable Suspension	paliperidone palmitate	546 mg/1.75 mL	207946	1	2020-06-24

US Patents and Regulatory Information for INVEGA TRINZA

INVEGA TRINZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-001	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-004	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-002	May 18, 2015		RX	Yes	Yes	10,143,693
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-003	May 18, 2015		RX	Yes	Yes	10,143,693

International Patents for INVEGA TRINZA

When does loss-of-exclusivity occur for INVEGA TRINZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Moldova, Republic of

Morocco

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVEGA TRINZA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016244801
Australia	2020239611
Australia	2022221405
Australia	2024227790
Brazil	112017021383
Canada	2925908

Supplementary Protection Certificates for INVEGA TRINZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0368388	07C0044	France		PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625
0368388	SPC/GB07/065	United Kingdom		PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081	C300491	Netherlands		PRODUCT NAME: PALIPERIDONPALMITAAT; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
0904081	91842	Luxembourg		91842, EXPIRES: 20220512
0904081	PA2011008	Lithuania		PRODUCT NAME: PALIPERIDONI PALMITAS; REGISTRATION NO/DATE: EU/1/11/672/001 - EU/1/11/672/006 20110304
0904081	CA 2011 00020	Denmark

INVEGA TRINZA Market Dynamics and Financial Trajectory (Paliperidone Palmitate 3-Month Injectable) — Exclusivity, Competition, and Revenue Exposure

Last updated: July 30, 2026

Executive summary: INVEGA TRINZA (paliperidone palmitate) is a long-acting injectable (LAI) antipsychotic with exclusivity rooted in branded formulation and delivery tech plus Janssen’s regulatory and patent strategy around LAI manufacturing. The product remains commercially concentrated in the US through Janssen, with demand driven by relapse prevention, office-based administration capacity, payer coverage of LAIs, and cross-switching from the 1‑month INVEGA SUSTENNA and the 6‑month INVEGA HAFYERA. Financial trajectory reflects LAI category growth but faces (i) loss of patent protections on earlier building blocks over time, (ii) biosimilar-type risks are not applicable to this small molecule LAI, and (iii) competitive pressure from other LAIs and payer-directed step edits. The risk to future revenue is mainly “evergreening vs. generic/LAI competition” rather than biologics pathway dynamics.

---

What drives INVEGA TRINZA demand and market dynamics in the US and EU?

Core demand drivers

• Relapse prevention and adherence: LAIs reduce missed doses versus oral paliperidone and other oral antipsychotics, particularly in patients with adherence history issues.
• Clinic workflow and switching: INVEGA TRINZA is a 3‑month administration interval, which is used to move stable patients off monthly INVEGA SUSTENNA dosing when prescriber and payer consider the step down in visit frequency.
• Payer coverage and medical-necessity framing: LAI coverage typically depends on diagnosis alignment and documentation of adherence risk or history of relapse. Once covered, LAIs can maintain entrenched formulary position.
• Safety and tolerability in the LAI segment: Paliperidone’s established tolerability profile supports clinician preference within schizophrenia and related indications where LAIs are used.

US and EU buying centers

• US: Hospital outpatient and specialty clinics drive administrations, with pharmacy benefit reimbursement tied to the drug’s acquisition cost, reimbursement policies, and utilization management. Wholesaler and channel mix affects realized net price.
• EU: National health services and large private payers dominate; tender cycles and negotiated ceilings can constrain pricing even as volume rises.

Competition within the LAI antipsychotic class

• Same-treatment alternatives: aripiprazole LAIs (monthly and 2‑month regimens), risperidone microspheres, and olanzapine pamoate create substitution pressure.
• Frequency-based switching: 1‑month LAIs offer tighter control but require more visits; 2‑month and 3‑month LAIs compete directly on clinic utilization and patient convenience.

---

What is the revenue trajectory for INVEGA TRINZA and how do LAI trends affect it?

Financial trajectory is shaped by four levers

1. Volume growth from LAI penetration
   • LAI adoption has increased in schizophrenia management as payers and prescribers prioritize adherence and relapse avoidance.
2. Net price and channel mix
   • Realized sales can be pressured by rebates, discounts, and channel inventory dynamics even when gross demand rises.
3. Switching funnel from INVEGA SUSTENNA
   • INVEGA TRINZA’s 3‑month interval benefits patients stabilized on monthly dosing, supporting sequential use.
4. Competitive substitution
   • When payers set LAI cost ceilings or when other LAIs demonstrate comparable outcomes with better pricing or administration logistics, switching can reduce INVEGA TRINZA share.

Segment-level performance pattern (how LAIs typically behave)

• LAI revenues often show stepwise inflections tied to formulary wins, contract renewals, and guideline uptake.
• Post-launch maturity commonly shifts growth from “new prescribers” to “repeat and switching conversions” from competing LAIs.

Commercial risk factors affecting future revenue

• Patent and formulation durability: even when core molecules are off-patent, sustained exclusivity can persist through LAI manufacturing process and formulation-specific protections.
• Payer utilization management: step edits and prior authorization can slow conversions to the 3‑month interval if the payer favors a different LAI schedule.

---

What patents protect INVEGA TRINZA and how do they influence financial exposure?

Patent estate impact model

• For an LAI, financial exposure depends on:
  1. Whether generic substitution is permitted at the same dosage strengths and injection regimen
  2. Whether “skinny-label” design-around strategies exist
  3. Whether manufacturing and particle/crystal properties are protected
  4. Whether switching barriers are “therapeutic interchangeability” or “practical clinic protocols.”

Why LAI patenting matters

• Generic LAI approval and launch require demonstration tied to performance attributes linked to formulation characteristics.
• Process and formulation patents can delay entrants or complicate approval pathways.

Business implication

• INVEGA TRINZA’s revenue durability is typically higher than oral products because payers and clinicians may be slower to switch, and because LAI-specific IP can restrict generic substitution timing.

(Note: This section focuses on market/IP linkage. A drug-specific patent-by-patent inventory requires Orange Book and litigation record extraction that is not provided here.)

---

When does INVEGA TRINZA lose exclusivity, and what is the generic entry risk timeline?

Exclusivity risk is multi-layered

• Regulatory exclusivity (US): can delay generic approvals regardless of patent status, tied to first approval and supplemental approvals.
• Patent expiration and “last expiring” protections: determines the earliest plausible launch timing for a non-authorized generic or Paragraph IV entrant.
• Launch readiness lag: even if patents expire, entrants need manufacturing validation, distribution contracting, and labeling finalization.

Generic entry risk profile for LAIs

• Generic risk is less immediate than oral small molecules because:
  • LAI manufacturing is complex
  • comparability and device-administration workflows need alignment
  • clinicians can require a transition plan and may resist early switching.

---

What is the Orange Book status of INVEGA TRINZA, and which listings block generic competition?

Orange Book controls the operational timeline

• The Orange Book listing determines:
  • Which patents are tied to each strength and dosage form
  • Which patents are “listed” vs. “expiring” vs. already expired
  • Whether there are multiple layers of protection across supplements

Business use

• For licensing and litigation strategy, the key is identifying the earliest non-expired listed patents for the relevant NDCs and strengths that would be asserted in a Paragraph IV challenge.

(Drug-specific Orange Book tables and NDC-linked expiration dates require record-level extraction not included in this input.)

---

How does INVEGA TRINZA compare with INVEGA SUSTENNA and INVEGA HAFYERA on payer fit and switching patterns?

INVEGA SUSTENNA vs. TRINZA

• Administration frequency: monthly vs. every-3-month dosing
• Switch trigger: TRINZA typically follows a stability period on SUSTENNA
• Payer logic: if the payer targets visit reduction and recognizes the 3‑month schedule as cost-neutral or cost-saving, TRINZA is favored.

INVEGA HAFYERA vs. TRINZA

• Administration frequency: 6‑month vs. 3‑month dosing
• Switch dynamics: clinicians may switch stable patients to the 6‑month regimen when coverage allows and when clinic staffing and long appointment scheduling align.
• Net impact: HAFYERA can cannibalize some TRINZA volume over time, depending on contract coverage and patient stability rates.

Financial implication

• INVEGA TRINZA’s long-run trajectory is partly a function of how many patients remain on the 3‑month regimen rather than being upgraded to HAFYERA.

---

How do other LAI antipsychotics affect INVEGA TRINZA market share and pricing?

LAI substitution drivers

• Net price competition: payer rebates and contract pricing can shift patient flow quickly.
• Tolerability and safety profiles: olanzapine LAI has distinct safety monitoring requirements that can drive preference for other LAIs, while aripiprazole LAIs compete on dosing intervals and partial agonist profile.
• Availability and logistics: inventory continuity and clinic administration training affect uptake.

Pricing pressure channels

• Formulary tiering: when payers place competing LAIs on lower cost-sharing tiers, INVEGA TRINZA net price can face downward pressure.
• Utilization management: prior authorization criteria can be tightened for higher-cost LAIs if the payer wants to steer to a favored competitor.

---

What patent litigation or settlements affect INVEGA TRINZA competition risk?

Why settlements matter

• Settlement agreements often:
  • set “carve-out” launch dates for entrants
  • include non-infringement standards that influence design-around strategies
  • require commitments on marketing or labeling timing.

LAI-specific litigation pattern

• For LAIs, disputes tend to focus on formulation/process claims and whether a proposed generic can achieve protected performance characteristics.

(No litigation docket or settlement record is included in the input, so no case-by-case mapping is provided.)

---

What FDA pathway considerations shape INVEGA TRINZA follow-on competition and utilization?

Regulatory controls that indirectly affect revenue

• Label breadth and safety monitoring: LAI labeling influences payer coverage acceptance and physician comfort.
• Manufacturing consistency and supply continuity: FDA enforcement actions or supply interruptions can temporarily move volume to competitors.
• Supplemental approvals: changes that expand labeled use can support volume; changes that affect stability or manufacturing specs can affect timelines for generic comparators.

---

Commercial outlook: where INVEGA TRINZA financial trajectory is most exposed

Three primary exposure points

1. Switching funnel economics
   • Growth depends on how many SUSTENNA-treated stable patients convert to TRINZA versus directly to HAFYERA as coverage evolves.
2. Formulary stability vs. rebate pressure
   • INVEGA TRINZA’s net sales are sensitive to payer contracting cycles and national accounts.
3. Generic entry and authorized competition timing
   • Even with delayed generic launches, authorized generics or limited competition can erode price before full generic entry.

What would signal downside acceleration

• A contract that forces step therapy away from 3‑month regimens toward cheaper alternatives.
• Broad coverage for a competing LAI with similar dosing interval and favorable rebate terms.
• Evidence of loss of market share in stable conversion to TRINZA and reduced “inertia.”

---

Key Takeaways

• INVEGA TRINZA’s market dynamics are driven by LAI adherence value, clinic and payer switching patterns, and competition within antipsychotic LAI schedules.
• Revenue trajectory is less about biologics-type pathways and more about patent-linked generic substitution risk and payer contracting.
• The key long-run variables are: conversion from INVEGA SUSTENNA, cannibalization or displacement by INVEGA HAFYERA and competitor LAIs, and contract-driven net price erosion.
• Generic competition risk is structurally moderated for LAIs by formulation and manufacturing complexity plus slower clinician switching.

---

FAQs

1) What clinical factors determine which schizophrenia patients are switched to INVEGA TRINZA from INVEGA SUSTENNA?
2) How do payer step edits and prior authorization policies typically affect access to INVEGA TRINZA?
3) Does INVEGA HAFYERA cannibalize INVEGA TRINZA sales, and under what coverage scenarios?
4) What are the main non-generic competitive threats to INVEGA TRINZA in the LAI antipsychotic market?
5) How do supply constraints or manufacturing events usually translate into short-term INVEGA TRINZA revenue volatility?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-30).
2. FDA. Drug Approval and Safety Communications for paliperidone palmitate LAI products. (Accessed 2026-07-30).
3. Janssen (Johnson & Johnson). INVEGA TRINZA (paliperidone palmitate) prescribing information. (Accessed 2026-07-30).